Tirzepatide for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2) — VialBase Research
high
- Tirzepatide 15mg produced 14.7% weight loss in T2DM patients
- Significant HbA1c reductions alongside weight loss
- First obesity trial combining weight and glycemic endpoints in T2DM
Summary
SURMOUNT-2 evaluated tirzepatide for weight management specifically in adults with obesity and type 2 diabetes. While weight loss was somewhat lower than in the non-diabetes SURMOUNT-1 trial (as expected, since T2DM typically attenuates GLP-1-mediated weight loss), results remained clinically significant with dual benefits for weight and glycemic control.
Key Findings
- Mean weight loss at 72 weeks: -12.8% (10mg) and -14.7% (15mg) vs -3.2% (placebo)
- Mean HbA1c reduction: -2.1% (10mg) and -2.1% (15mg) vs -0.5% (placebo)
- 81.6% (10mg) and 86.2% (15mg) achieved ≥5% weight loss
- 30.2% (10mg) and 40.0% (15mg) achieved ≥20% weight loss
- Consistent improvements in cardiometabolic markers
- Safety profile consistent with prior tirzepatide trials
Methodology
Double-blind, placebo-controlled, phase 3 RCT in 938 adults with BMI ≥27 and T2DM (HbA1c 7-10%). Randomized 1:1:1 to tirzepatide 10mg, 15mg, or placebo weekly for 72 weeks. Co-primary endpoints: percent weight change and ≥5% weight loss at 72 weeks.
Limitations
- Only tested 10mg and 15mg doses (no 5mg arm)
- T2DM patients typically lose less weight on GLP-1 therapies — as seen here vs SURMOUNT-1
- No active comparator (semaglutide or other)
- Concomitant diabetes medications varied across participants
- Predominantly recruited from specialty clinics
Relevance to Content
Important for content targeting the T2DM+obesity overlap population. Shows that while weight loss is somewhat attenuated in diabetes (14.7% vs 20.9% in SURMOUNT-1), dual weight/glycemic benefits make tirzepatide particularly valuable in this population. Useful for articles about metabolic health beyond weight alone.
See Also
- Parent compound: Tirzepatide
- Semaglutide